These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
157 related items for PubMed ID: 27380475
21. Real-world evidence of lupus anticoagulant testing: simultaneous positivity of diluted Russell's viper venom time and silica clotting time increases thrombotic risk prediction. Lee Y, Gu JY, Kim HK. J Thromb Thrombolysis; 2022 Aug; 54(2):318-322. PubMed ID: 35841477 [Abstract] [Full Text] [Related]
22. Paired APTTs of low and high lupus anticoagulant sensitivity permit distinction from other abnormalities and achieve good lupus anticoagulant detection rates in conjunction with dRVVT. Kumano O, Amiral J, Dunois C, Peyrafitte M, Moore GW. Int J Lab Hematol; 2019 Feb; 41(1):60-68. PubMed ID: 30248243 [Abstract] [Full Text] [Related]
24. Heterogeneity of lupus anticoagulant (LA) antibodies: LA activity in dilute Russell's Viper Venom Time and dilute Kaolin Clotting Time detect different populations of antibodies in patients with the "antiphospholipid" syndrome. Kandiah DA, Krilis SA. Thromb Haemost; 1998 Aug; 80(2):250-7. PubMed ID: 9716148 [Abstract] [Full Text] [Related]
26. The risk of thrombosis in patients with lupus anticoagulants is predicted by their specific coagulation profile. Galli M, Finazzi G, Norbis F, Marziali S, Marchioli R, Barbui T. Thromb Haemost; 1999 May; 81(5):695-700. PubMed ID: 10365739 [Abstract] [Full Text] [Related]
27. Laboratory identification of lupus anticoagulants using the combination of activated partial thromboplastin time and Russell's viper venom at two phospholipid concentrations. Akkawat B, Chantarangkul V, Rojnuckarin P, Juntiang J. J Med Assoc Thai; 2003 Jun; 86 Suppl 2():S451-8. PubMed ID: 12930024 [Abstract] [Full Text] [Related]
28. Variability and diagnostic utility of antiphospholipid antibodies including lupus anticoagulants. Favaloro EJ. Int J Lab Hematol; 2013 Jun; 35(3):269-74. PubMed ID: 23590654 [Abstract] [Full Text] [Related]
32. Laboratory evaluation of anti-phospholipid syndrome: a preliminary prospective study of phosphatidylserine/prothrombin antibodies in an at-risk patient cohort. Heikal NM, Jaskowski TD, Malmberg E, Lakos G, Branch DW, Tebo AE. Clin Exp Immunol; 2015 May; 180(2):218-26. PubMed ID: 25522978 [Abstract] [Full Text] [Related]
33. Clinical significance of antiphospholipid protein antibodies. Receiver operating characteristics plot analysis. Musial J, Swadzba J, Motyl A, Iwaniec T. J Rheumatol; 2003 Apr; 30(4):723-30. PubMed ID: 12672190 [Abstract] [Full Text] [Related]
34. Frequency of vascular and pregnancy morbidity in patients with low vs. moderate-to-high titers of antiphospholipid antibodies. Ofer-Shiber S, Molad Y. Blood Coagul Fibrinolysis; 2015 Apr; 26(3):261-6. PubMed ID: 25526601 [Abstract] [Full Text] [Related]
39. Diagnostic accuracy of silica clotting time method for lupus anticoagulant in a clinical population with various symptoms of antiphospholipid syndrome. Averina M, Johannesen S, Brox J. Lupus; 2016 Apr; 25(4):418-22. PubMed ID: 26612052 [Abstract] [Full Text] [Related]
40. Alternative assays to dRVVT and aPTT for lupus anticoagulant detection. Moore GW. Am J Hematol; 2020 Aug; 95(8):992-998. PubMed ID: 32311119 [Abstract] [Full Text] [Related] Page: [Previous] [Next] [New Search]